Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levoketoconazole in Endogenous Cushing's Syndrome
NCT01838551Phase 3Completed
- Sponsor
- Strongbridge Biopharma
- Start
- Aug 2014
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of levoketoconazole in Cushing syndrome (CS), sponsored by Strongbridge Biopharma. Primary endpoint: Proportion of subjects with normal Urinary Free Cortisol at 6 months. Started Aug 2014; status: completed.
02
Drugs
levoketoconazole
03
Conditions
Cushing syndrome (CS)
Beyond the preview
Go deeper on NCT01838551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01838551.